This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
In recognition of the 5th anniversary of the AONN+ Metrics, we present a review of the metrics designed to measure the impact of navigation on clinical outcomes.